Expert Interviews

Our network connects providers, health plans, and life science companies to deliver seamless care that benefits everyone

Panelists discuss how delaying intervention between stage II and stage III T1D can result in irreversible β-cell loss, higher rates of complications, and poorer overall outcomes for patients.

Panelists discuss how understanding the stages of type 1 diabetes (T1D) progression is crucial for early intervention, with a focus on delaying disease advancement through proactive treatments like teplizumab.

Panelists discuss how delaying intervention in stage 2 T1D can lead to faster disease progression, increased risk of complications like diabetic ketoacidosis, and greater long-term burden on patient health and quality of life.

Panelists highlight the burden of type 1 diabetes including the significant physical, emotional, and financial challenges faced by patients and their families, emphasizing the need for early intervention and proactive management strategies.

A geriatric psychiatrist talks about the importance of asking caregivers about behavior in order to understand and treat agitation in Alzheimer dementia.

William Grady, MD, highlights ongoing efforts to improve test sensitivity and developments of new blood-based tests for early detection of CRC.

William Grady, MD, coauthor of the ECLIPSE study, discusses the use of non-invasive cfDNA blood-based tests for CRC screening in older adults.

With the recent surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.